http://www.cnr.it/ontology/cnr/individuo/prodotto/ID304970

Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (Articolo in rivista)

Type

Articolo in rivista (Classe)
Prodotto della ricerca (Classe)

Label

Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (Articolo in rivista) (literal)

Anno

2013-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

10.1097/RLU.0b013e318286bd84 (literal)

Alternative label

De Luca, Serena; Fonti, Rosa; Palmieri, Giovannella; Federico, Piera; Del Prete, Giuseppina; Pacelli, Roberto; Pace, Leonardo; De Placido, Sabino; Salvatore, Marco; Del Vecchio, Silvana (2013)
Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors
in Clinical nuclear medicine
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

De Luca, Serena; Fonti, Rosa; Palmieri, Giovannella; Federico, Piera; Del Prete, Giuseppina; Pacelli, Roberto; Pace, Leonardo; De Placido, Sabino; Salvatore, Marco; Del Vecchio, Silvana (literal)

Pagina inizio

354 (literal)

Pagina fine

358 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

38 (literal)

Rivista

Clinical nuclear medicine (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

5 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

5 (literal)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR)-IBB; University of Naples Federico II; University of Naples Federico II, University of Naples Federico II; University of Naples Federico II; University of Salerno; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II. (literal)

Titolo

Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (literal)

Abstract

PURPOSE: This study aimed to test the role of combined imaging with 18F-FDG-PET/CT and 111In-octreotide SPECT in characterizing thymic epithelial tumors (TETs). METHODS: We evaluated 20 patients with newly diagnosed TETs who had undergone concomitant 18F-FDG-PET/CT and 111In-octreotide SPECT. Thymic epithelial tumors were classified by World Health Organization (WHO) as low-risk thymomas (5), high-risk thymomas (4), and thymic carcinomas (11, among which 6 neuroendocrine tumors). Patients were staged according to Masaoka system. 18F-FDG-PET/CT was performed and SUV(max) of primary tumors was recorded. 111In-octreotide SPECT of the thorax was performed, and tumor-to-background ratio was determined on the 24-hour coronal sections. RESULTS: All patients showed increased 18F-FDG uptake in mediastinal lesions. SUV(max) were significantly correlated with WHO classification (r = 0.66, P < 0.01) and with Masaoka stage (r = 0.60, P < 0.01). SUV(max) of low-risk thymomas (mean [SD], 2.87 [0.83]) were significantly lower than those of high-risk thymomas (mean [SD], 7.21 [1.73], P < 0.01) and of thymic carcinomas (mean [SD], 9.39 [5.80], P < 0.05), whereas no significant difference was found between high-risk thymomas and thymic carcinomas. SUV(max) of all high-risk thymomas and thymic carcinomas was 4.5 or greater. All primary tumors were detected by In-octreotide SPECT, and tumor-to-background ratios ranged between 1.67 and 10.10. No statistically significant correlation was found between tumor-to-background ratios and WHO classification (r = 0.24, P = 0.36) and Masaoka stages (r = 0.31, P = 0.23). However tumor-to-background ratios of thymic neuroendocrine tumors (mean [SD], 5.71 [3.09]) were significantly higher than those of all other TETs with SUV(max) of 4.5 or greater (mean [SD], 2.41 [0.56]; P < 0.05). CONCLUSIONS: 18F-FDG-PET/CT scan allows to differentiate high-risk epithelial tumors and thymic carcinomas from low-risk thymomas, whereas 111In-octreotide SPECT may identify neuroendocrine tumors among those showing high 18F-FDG uptake. (literal)

Prodotto di